Drug Manufacturers - Specialty & Generic · Healthcare
Board Member, CEO
2026-05-04–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Apimeds Pharmaceuticals US, Inc. publishes a filing, an earnings call transcript or a press release.
Get APUS alertsSungjoon Chae is recorded as Board Member at Apimeds Pharmaceuticals US, Inc. (APUS) since September 10, 2026 and CEO at Apimeds Pharmaceuticals US, Inc. (APUS) since May 4, 2026. Apimeds Pharmaceuticals US, Inc. reported in an 8-K filed September 11, 2026 that Sungjoon Chae was appointed member of the Board, effective September 10, 2026. Apimeds Pharmaceuticals US, Inc. reported in an 8-K filed May 5, 2026 that Sungjoon Chae was appointed Co-Chief Executive Officer, effective May 4, 2026. Apimeds Pharmaceuticals US, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Apimeds Pharmaceuticals US, Inc. includes Vin Menon (CEO and Board Member), Youngjik Cho (CEO, Chairman and Board Member), Eric Sherb (CFO) and 3 others.
“On September 10, 2026, pursuant to the Settlement Agreement, as amended by the Amendment (each as defined in Item 1.01 above), the Board appointed Sungjoon Chae to serve as a member of the Board, effective as of such date.”
“On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), the board of directors of the Company (the “Board”) appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.”
2026-09-10–present
2026-05-04–present
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member, CEO
2026-05-04–present